It has been demonstrated that calcium dobesilate binds to the heparin-binding domain of FGF-1, thus reducing its activity (2), and it has been demonstrated to be effective for the treatment of rosacea (5) and psoriasis (6), which are clinical manifestations associated with excessive angiogenesis and the overexpression of vascular endothelial growth factor (VEGF). The gene discussed is VEGFA; the disease is rosacea.